Healthcare Industry News: cardiopulmonary
News Release - March 9, 2007
Gilead Sciences Announces New Appointments within Executive TeamFOSTER CITY, Calif.--(HSMN NewsFeed)--Gilead Sciences, Inc. (Nasdaq:GILD ) announced today the appointment of Norbert W. Bischofberger, PhD to the position of Executive Vice President, Research and Development and Chief Scientific Officer and the appointment of John F. Milligan, PhD to the position of Chief Operating Officer.
Dr. Bischofberger joined Gilead in 1990 from Genentech, Inc. He has held roles of increasing responsibility within the Research and Development organization at Gilead, and was most recently appointed Executive Vice President, Research and Development in 2000. He received his PhD in Organic Chemistry at Eidgenossische Technische Hochschule in Zurich, Switzerland. As Chief Scientific Officer, Dr. Bischofberger will oversee all aspects of Gilead's research and development efforts, including Gilead's recently acquired Seattle, Washington and Westminster, Colorado programs in the fields of respiratory and cardiopulmonary therapeutics and the company's Edmonton, Alberta operations. A. Bruce Montgomery, MD, Senior Vice President, Head of Respiratory Therapeutics will now report to Dr. Bischofberger.
Dr. Milligan also joined Gilead in 1990, beginning his career at the company as a Research Scientist. He has held leadership roles in Project Management and Corporate Development. Dr. Milligan was appointed Senior Vice President and Chief Financial Officer in 2002 and was promoted to Executive Vice President in 2003. He received a Doctorate in Biochemistry from the University of Illinois and was an American Cancer Society Postdoctoral fellow at the University of California at San Francisco. In his new role, Dr. Milligan will oversee Gilead's commercial organization, manufacturing, finance and business operations. Kevin Young, Executive Vice President, Commercial Operations will continue to lead Gilead's commercial organization, which he has grown substantially since joining the company in 2004, and will report in this role to Dr. Milligan. Anthony Caracciolo, Senior Vice President, Manufacturing will also report to Dr. Milligan. Dr. Milligan will continue to serve in the role of Chief Financial Officer until a new CFO is identified.
"Gilead has grown tremendously over the last several years, and these organizational changes will ensure our company is positioned to continue delivering new, innovative therapies to those patients most in need," said John C. Martin, PhD, President and Chief Executive Officer, Gilead Sciences. "I am confident in the abilities of Gilead's senior leadership team - Norbert, John, Kevin, Gregg Alton, Senior Vice President and General Counsel and Kristen Metza, Vice President, Human Resources - to guide the continued success of our company."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
Source: Gilead Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.